330792-93-3

Basic information

• Product Name: 4-(4-BROMOPHENOXY)BENZONITRILE
• Synonyms: 4-(4-BROMOPHENOXY)BENZONITRILE
• CAS NO: 330792-93-3
• Molecular Formula: C₁₃H₈BrNO
• Molecular Weight: 274.11
• Mol File: 330792-93-3.mol
• Article Data: 14

Chemical Properties

• Melting Point: 78-79 °C
• Boiling Point: 369.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-(4-BROMOPHENOXY)BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMOPHENOXY)BENZONITRILE(330792-93-3)
• EPA Substance Registry System: 4-(4-BROMOPHENOXY)BENZONITRILE(330792-93-3)

Safety Data

• Hazardous Substances Data: 330792-93-3(Hazardous Substances Data)

Upstream product

• 767-00-0 4-cyanophenol 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 1197-19-9 4-cyano-N,N-dimethylaniline 
• 106-41-2 4-bromo-phenol 
• 459-57-4 4-fluorobenzaldehyde 
• 1194-02-1 4-fluorobenzonitrile 
• 619-72-7 4-nitrobenzonitrile 

Downstream Products

• 330792-94-4 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)benzonitrile 
• 1185096-22-3 4-(4-bromophenoxy)benzylamine hydrochloride 
• 1207731-17-6 2-(4-(4-cyanophenoxy)phenyl)benzo[b]thiophene-6-carbonitrile 
• 1207731-33-6 tert-butyl 6-chloro-2-(4-(4-cyanophenoxy)phenyl)-1H-indole-1-carboxylate 
• 947162-05-2 4-(4-cyanophenoxy)phenylboronic acid 

Relevant articles and documents

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.

From Anilines to Aryl Ethers: A Facile, Efficient, and Versatile Synthetic Method Employing Mild Conditions

We have developed a simple and direct method for the synthesis of aryl ethers by reacting alcohols/phenols (ROH) with aryl ammonium salts (ArNMe3+), which are readily prepared from anilines (ArNR′2, R′=H or Me). This reaction proceeds smoothly and rapidly (within a few hours) at room temperature in the presence of a commercially available base, such as KOtBu or KHMDS, and has a broad substrate scope with respect to both ROH and ArNR′2. It is scalable and compatible with a wide range of functional groups.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).